In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

Member Benefit

This content is only available year-round to ESC Professional Members, Fellows of the ESC, and Young Combined Members

Men who live alone have poor anticoagulation control: results from Danish registries.

Session Poster Session 5

Speaker Doctor Anders Nissen Bonde

Event : ESC Congress 2019

  • Topic : arrhythmias and device therapy
  • Sub-topic : Oral Anticoagulation
  • Session type : Poster Session

Authors : AN Bonde (Copenhagen,DK), J Bjerre (Copenhagen,DK), M Proietti (Milan,IT), G Gislason (Copenhagen,DK), GYH Lip (Liverpool,GB), M Hlatky (Stanford,US)

A.N. Bonde1 , J. Bjerre1 , M. Proietti2 , G. Gislason1 , G.Y.H. Lip3 , M. Hlatky4 , 1Gentofte University Hospital - Copenhagen - Denmark , 2Cardiology Center Monzino IRCCS, Department of Neuroscience - Milan - Italy , 3Institute of Cardiovascular Medicine & Science of Liverpool - Liverpool - United Kingdom , 4School of Medicine, Department of Health Research and Policy - Stanford - United States of America ,

Oral Anticoagulation

European Heart Journal ( 2019 ) 40 ( Supplement ), 2969

Background: Efficacy and safety of vitamin K antagonists (VKAs) depend on quality of anticoagulation control, usually measured as time in therapeutic range (TTR). Factors that predict low TTR on VKAs could be used to identify patients who might benefit from interventions, or who would be better treated with a non-VKA oral anticoagulant (NOAC). Patients living alone may have difficulties in taking their medications, managing their diets, or coming to clinic for monitoring.

Purpose: To assess influence of cohabitation status on TTR with VKA among men and women.

Methods: We identified all Danish patients with atrial fibrillation (AF) who initiated VKA between 1997 and 2012, and studied patients who had 6 months of continuous VKA use and international normalized ratio (INR) monitoring. Patients were divided according to sex and whether they lived alone or with others. We calculated TTR using the Rosendaal method, and INR variability using Fihns method. We used a linear regression model to test for associations between TTR and covariates, and adjusted for age, income, medications and comorbidities.

Results: We identified 4,772 AF patients with 6 months of continuous VKA use and INR monitoring. 713 (15%) were men living alone, 1,073 (23%) were women living alone, 2,164 (45%) were men not living alone and 822 (17%) were women not living alone. INR was measured a median of 11 (interquartile range 8–15) times during the 180 days of VKA use, but men who lived alone had 0.6 (95% confidence interval (CI): 0.2 to 1.2) fewer INR measurements during the period. Median TTR was lowest among men living alone (57.2%), followed by women living alone (58.8%), women not living alone (61.0%) and men not living alone (62.5%). After multivariable adjustment, men who lived alone had a 3.6% (CI −5.6 to −1.6) lower TTR compared with men not living alone, but women who lived alone did not have significantly lower TTR (P=0.80) compared with women not living alone. Living alone had significantly greater effect on TTR among men than among women (interaction P=0.02). Men living alone also had higher adjusted INR variability (0.2, CI 0.0 to 0.4) compared with men not living alone.

Conclusion: Living alone was significantly related to low quality of anticoagulation control among men, but not among women.

Member Benefit

This content is only available year-round to ESC Professional Members, Fellows of the ESC, and Young Combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now
logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are